薄芝糖肽对热性惊厥患儿的免疫调节作用及临床疗效观察  

Immune Regulation and Clinical Efficacy of Bozhiglycopeptides in Children with Febrile Seizures

作　　者：周小琳[1] 欧榕琼[1] 李平甘[1] 何展文[1] 李栋方[1] ZHOU Xiao-lin;OU Rong-qiong;LI Ping-gan;HE Zhan-wen;LI Dong-fang(Department of Children＇s Neurology, the Memorial Hospital of Sun Yat-sen University, Guangzhou , 510120)

机构地区：[1]中山大学孙逸仙纪念医院小儿神经内分泌专科,510200

出　　处：《岭南急诊医学杂志》2018年第3期249-251,共3页Lingnan Journal of Emergency Medicine

基　　金：广东省自然博士启动项目资助(2015A030310047)

摘　　要：目的:探讨薄芝糖肽对热性惊厥患儿外周血免疫指标的影响及临床疗效。方法:选取本科室收治的60例热性惊厥患儿,随机分为两组,对照组30例患儿接受常规治疗,治疗组30例患儿在常规治疗基础上给予薄芝糖肽治疗。两组患儿均在治疗前后采血检测外周血CD19^+B、CD20^+B、CD4^+T、CD8^+T、CD4^+/CD8^+、IgA、IgM、IgG表达水平。治疗结束后继续随访1年,观察两组患儿在发热时热性惊厥发作情况。结果:薄芝糖肽治疗后,治疗组CD19^+B、CD20^+B细胞比例明显降低,CD4^+T、CD4^+/CD8^+比例明显升高,CD8^+T细胞比例明显降低,同时体液免疫指标IgA、IgG含量明显升高(P<0.05);而对照组以上免疫指标治疗前后均无明显改变(P>0.05)。治疗结束随访1年治疗组临床有效比例明显高于对照组(P<0.05)。结论:薄芝糖肽能调节热性惊厥患儿的免疫功能并改善临床症状。Objective ： To analyzethe expressions of peripheral blood lymphocyte subsets and the effect of Bozhiglyco- peptides in children with febrileseizures. Methods ： Sixrty patients with febrile seizures admitted to our department were randomly divided into two groups. 30 patients in the control group received routine treatment, while another 30 patients in the treatment group were treated with Bozhiglycopeptide on the basis of routine treatment. The expressions of CD 19＋B, CD20＋B, CD4＋T, CD8＋T, CD4＋/CD8＋, IgA, IgM, and IgG in peripheral blood of the two groups were measured before and after treatment. After the treatment was completed, follow-up was continued for 1 year. The episodes of febrile con- vulsions in the two groups were observed during fever. Results ： After treatment with Bozhiglyeopeptide, the expressions of CD19＋B and CD20＋ B cells in the treatment group significantly decreased （P〈0.05） , the expressions of CD4＋T and CD4＋/CD8＋ signifieantlyincreased （P〈0.05） , while the levels of CD8＋ T cells significantlydeereased （P〈0.05） and the humoral immune index signifieantly increased in lgA and IgG （P〈0.05）. However, there was no significant ehange in immune parameters in the control group （P〉0.05）. The rateof elinieally effieieneyin the treatment group was significantly higher that in the control group at the end of treatment for l year （P〈0.05）. Conclusion： Boziglycopeptide can regulate immune function and improve clinical symptoms in children with febrile seizures.

关 键 词：热性惊厥 薄芝糖肽 淋巴细胞亚群 体液免疫 

分 类 号：R720.597[医药卫生—急诊医学]